Anticonvulsant

Australia has seen a surge in vitamin D testing of children, with similar trends reported for adults around the world. GPs are now being urged not to test for vitamin D unnecessarily. So when is low vitamin D a potential concern? And when might you need to get your levels tested?

How much vitamin D do we need?

• Vitamin D also has many other roles, including helping our immune defences and contributing to DNA repair and cell differentiation.
• We can thank the sun for most of our vitamin D. A chemical in our skin called 7-dehydrocholesterol is converted to vitamin D after contact with UVB radiation from the sun.
• While we get some vitamin D also through our diet, this makes a relatively small contribution.
• It’s difficult to get much more than one-third of our daily vitamin D requirement from diet without supplementation.

Why avoid vitamin D deficiency?

• Prolonged, severe vitamin D deficiency will lead to softening of bone tissue and cause diseases such as rickets (children) and osteomalacia (adults).
• However, avoiding low concentrations is likely to be good for many aspects of health, with consistent evidence suggesting benefits for infectious diseases and autoimmune conditions such as multiple sclerosis.

Who is at risk of deficiency?

• The two main reasons for vitamin D deficiency typically relate to: 1. not getting (enough) vitamin D through sun exposure.
• Deficiency risk can be high for anyone who is housebound, such as older or disabled people in residential care.
• The risk of deficiency increases if we always cover our skin carefully by modest cultural dress, and also dark skin pigmentation is known to reduce vitamin D synthesis.

Am I getting enough sun exposure?

• In Australia, it is possible to get enough vitamin D from the sun throughout the year.
• Read more:
  Why you need more Vitamin D in the winter

  During winter, catching enough sun can be difficult, especially if you spend your days confined indoors.

• This is because sunlight exposure can only help produce vitamin D if the UVB rays reach us at the correct angle.

Why does excess vitamin D testing matter?

• Excessive testing is also a waste of health-care resources, with one single test costing about the same as a years’ worth of vitamin D supplementation.
• Very often, we can make relatively small changes to our lifestyles to reduce the risks of vitamin D deficiency.

• Central target engagement, as the treatment group was easily identified in blinded data using qEEG power signature.
• “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate.
• The Phase 1 study was conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies.
• The study evaluated the safety, tolerability, pharmacokinetic (PK), and food effect of BMB-101 in healthy volunteers.

• Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
• In addition KRM-II-81 is active in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.
• 385:50-61 document the preclinical effects and tolerability of structural analogs of KRM-II-81.
• In established rat models predicting efficacy in essential tremor and in tremor associated with Parkinson’s Disease, MP-III-024 was an effective anti-tremor compound.

• Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021.
• Initial implant revenue is expected to be approximately $9.8 million, representing growth of 15% compared to $8.5 million in the fourth quarter of 2021.
• Replacement implant revenue is expected to be approximately $1.4 million, representing a decline of 44% compared to $2.5 million in the fourth quarter of 2021.
• Additionally, NeuroPace announced the appointment of Dr. Uri Geiger to its Board of Directors, effective January 5, 2023.